Modified EKLF Polypeptide Inhibiting Sumoylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of longevity genes is limited, and few have been identified, making it challenging to develop effective anti-aging and anti-cancer therapies, while existing treatments for cellular proliferative disorders and cancer are not fully effective in extending lifespan or preventing tumor metastasis.
Innovation Solution
A synthetic polypeptide based on a modified Erythroid Kruppel-like factor (EKLF) polypeptide with amino acid modifications at sumoylation or phosphorylation sites, such as K74R, is used to inhibit sumoylation or phosphorylation, reducing tumor occurrence and metastasis, and potentially treating aging-related issues like graying hair, muscle weakness, and osteoporosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type EKLF is used to treat cellular proliferative disorders, then tumor growth is inhibited, but sumoylation-mediated transcriptional repression is lost reducing therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues at sumoylation sites (lysine to arginine substitutions at positions 74, 54, and other conserved sites) to prevent sumoylation while maintaining the polypeptide's structural integrity and transcriptional regulation capacity. This chemical modification of key parameters resolves the contradiction by eliminating the harmful sumoylation effect while preserving therapeutic function.
Solution Approach 2:
The invention converts the harmful sumoylation process into a benefit by identifying and modifying the specific lysine residues responsible for sumoylation. By substituting these residues with arginine, the patent prevents pathological sumoylation that would otherwise promote cellular proliferation, while maintaining necessary transcriptional repression functions for anti-cancer therapy.
2Productivity
If sumoylation is enhanced to increase transcriptional repression, then anti-proliferative activity is improved, but lifespan is reduced due to accelerated aging pathways
Solution Approach 1:
The patent modifies the sumoylation parameter by substituting lysine residues with arginine at critical positions, thereby preventing sumoylation while maintaining transcriptional repression capability. This parameter change resolves the contradiction by decoupling sumoylation status from anti-proliferative activity, allowing sustained therapeutic effect without the harmful aging-associated consequences of enhanced sumoylation.
3Reliability
If multiple sumoylation sites are modified to completely prevent sumoylation, then anti-cancer efficacy is maximized, but protein stability and function are compromised
Solution Approach 1:
The patent applies targeted parameter changes by substituting only the critical sumoylation-site lysine residues with arginine, rather than modifying all basic residues. This selective modification prevents sumoylation at pathogenic sites while preserving overall protein structure, stability, and essential functions. The conservative nature of the lysine-to-arginine substitution (both being positively charged amino acids) maintains protein stability while achieving the desired anti-sumoylation effect.
Data Source
Figure 1A
Figure 1B~1D
Figure 2A~2B
AI summary
The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis